Abstract
The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Current Alzheimer Research
Title:Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Volume: 9 Issue: 8
Author(s): A. Salva, M.O. Rikkert, M. Tsolaki, P.-J. Ousset, F. Pasquier, J.M. Ribera-Casado, A.S. Rigaud, P. Robert, G. Rodriguez, E. Salmon, P. Martinez-Lage, P. Scheltens, A. Schneider, A. Sinclair, L. Spiru, J. Touchon, D. Zekry, B. Winblad, S. Andrieu, M. Boada, L. Hausner, L. Frolich, C. Cantet, V. Gardette, E. Reynish, S. Gillette, E. Aguera-Morales, S. Auriacombe, B. Vellas, R. Bullock, J. Byrne, V. Camus, A. Cherubini, M. Eriksdotter-Jonhagen, G.B. Frisoni, S. Hasselbalch and R.W. Jones
Affiliation:
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Abstract: The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Export Options
About this article
Cite this article as:
Salva A., Rikkert M.O., Tsolaki M., Ousset P.-J., Pasquier F., Ribera-Casado J.M., Rigaud A.S., Robert P., Rodriguez G., Salmon E., Martinez-Lage P., Scheltens P., Schneider A., Sinclair A., Spiru L., Touchon J., Zekry D., Winblad B., Andrieu S., Boada M., Hausner L., Frolich L., Cantet C., Gardette V., Reynish E., Gillette S., Aguera-Morales E., Auriacombe S., Vellas B., Bullock R., Byrne J., Camus V., Cherubini A., Eriksdotter-Jonhagen M., Frisoni G.B., Hasselbalch S. and Jones R.W., Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251066
DOI https://dx.doi.org/10.2174/156720512803251066 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein, Oxidative Stress, mTOR Signaling, and Synaptic Protein)
Mini-Reviews in Medicinal Chemistry Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz
Current HIV Research Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline
Current Medicinal Chemistry Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy The Interaction of DNA-Binding Ligands with Trinucleotide-Repeat DNA: Implications for Therapy and Diagnosis of Neurological Disorders
Current Topics in Medicinal Chemistry Genes and Hypertension
Current Pharmaceutical Design EDITORIAL: Neuroprotection Mechanisms and their Potential Applications
Current Neuropharmacology Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer’s Disease
Current Alzheimer Research Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Diet and Neurocognition: Review of Evidence and Methodological Considerations
Current Aging Science Role of DAP12 in Innate and Adaptive Immune Responses
Current Pharmaceutical Design Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design